
A study examined uPTM-FetA, a post-translationally modified fetuin-A fragment in urine, as a marker for kidney function decline in type 2 diabetes patients. Using data from two independent cohort studies in Taiwan and the Netherlands, established a uPTM-FetA cutoff via ELISA. Patients with high uPTM-FetA levels had a significantly increased risk of renal function decline, irrespective of age, sex, and other factors. These findings suggest uPTM-FetA's potential as a clinical marker for tracking kidney function progression in type 2 diabetes patients, with implications for improved patient care.
Like
Save
Share